Startups 

Dedicated to revolutionizing Chronic Obstructive Pulmonary Disease (COPD) treatment through regenerative medicine, with its lead compound, MC002, designed to promote alveolar epithelial cell regeneration and lung tissue repair.

MimeCure B.V. is an innovative biotechnology company dedicated to advancing the treatment of chronic lung diseases, with a particular focus on chronic obstructive pulmonary disease (COPD). Founded in collaboration with researchers from the University of Groningen, MimeCure aims to revolutionize the way COPD is treated by developing the first regenerative therapy that targets the underlying causes of lung tissue damage and promotes natural lung repair.

At the core of MimeCure’s approach is the development of a novel therapeutic agent based on the active fragment of osteoglycin (OGN), a naturally occurring protein known for its regenerative properties. OGN plays a critical role in the regeneration of alveolar epithelial cells and the restoration of lung tissue, both of which are severely compromised in COPD patients. Preclinical studies have demonstrated the powerful regenerative effects of OGN’s active fragment (referred to as MC002) in models of lung damage, showing promising results in enhancing lung repair, improving lung function, and potentially reversing the damage caused by COPD. This makes MC002 the first of its kind as a regenerative treatment for a disease that currently has no cure.

MimeCure’s mission is to develop MC002 into a commercially viable therapeutic that can be administered via inhalation, ensuring targeted delivery directly to the lungs. The company is working towards optimizing the formulation of MC002, including the development of a dry powder inhaler for easy and effective delivery. This approach allows for higher local concentrations of the therapeutic agent in the lungs while minimizing systemic side effects, making it a safer and more effective treatment option for patients.

In addition to developing MC002, MimeCure is committed to understanding the broader mechanisms of action of osteoglycin in lung regeneration and exploring its potential for treating other lung diseases, such as pulmonary fibrosis, cystic fibrosis, and acute respiratory distress syndrome (ARDS). By focusing on the natural communication pathways between lung cells and harnessing the body’s own regenerative capabilities, MimeCure seeks to address not only COPD but also a range of respiratory conditions that currently lack effective treatments.

MimeCure’s business model is centered on advancing its pipeline through key clinical milestones, building strategic partnerships with pharmaceutical companies, and seeking regulatory approvals. The company plans to initiate Phase I clinical trials in the near future, with the goal of establishing the safety and efficacy of MC002 in humans. By leveraging its deep expertise in lung biology, regenerative medicine, and pharmaceutical development, MimeCure aims to transform the standard of care for COPD and other chronic lung diseases.

Ultimately, MimeCure’s vision is to provide millions of patients suffering from COPD with a life-changing therapy that not only alleviates symptoms but also addresses the root cause of the disease, offering the potential for true lung regeneration. In doing so, the company hopes to reduce the immense societal and economic burden of COPD while significantly improving
patient outcomes.

BioBusiness Masterclass

Karpervijver 17, 3703 CJ Zeist, The Netherlands

office@biobusinessmasterclass.nl